The RNA therapeutics market is on track for rapid growth, driven by the increasing prevalence of chronic diseases, growing investments in RNA-based research and development, and the rising demand for personalized medicine. This market is expected to reach a value of $948 million by 2031, fueled by the success of mRNA vaccines and therapies in clinical trials.
The global single-cell analysis market is expected to grow at a CAGR of 13.9% from 2024 to 2034, driven by the increasing demand for precision medicine and cancer research. Single-cell analysis is essential for understanding complex biological processes at the cellular level, allowing for early diagnosis of diseases and personalized treatment strategies.
The global AI in pharma and biotech market is projected to reach US$ 13.1 billion by 2034, driven by the rapid adoption of AI-powered tools for drug discovery, clinical trials, and personalized medicine. AI is transforming drug development, improving clinical trial efficiency, and enabling personalized treatment plans.
The global targeted therapeutics market is experiencing significant growth, driven by increasing cancer cases and a surge in product approvals. This market is expected to reach US$ 118.6 Billion by 2034, driven by a 6.4% CAGR. The report highlights the rise of precision medicine and the potential of targeted therapies in treating autoimmune and inflammatory diseases.
A groundbreaking genetic test holds the promise of revolutionizing prostate cancer detection, potentially saving thousands of lives annually. This simple at-home saliva test identifies individuals at the highest risk of developing the disease, enabling earlier diagnosis and more effective treatment. The landmark study reveals that this test surpasses the current blood test offered by GPs in detecting prostate cancer, signaling a potential shift in screening strategies.
Gordian Biotechnology, an in vivo drug discovery and development company, has unveiled an innovative platform that enables patient-predictive in vivo screening of gene targets for FDA-recognized diseases of aging at an unprecedented scale. This groundbreaking platform has the potential to revolutionize the development of therapies for a wide range of age-related ailments.
Artificial intelligence (AI) is revolutionizing healthcare, particularly in the detection and treatment of cancer. Early screening for breast cancer and precise dosing of immunotherapy are now possible with AI assistance, saving lives.
Longitudinal multi-omics monitoring (LMOM) is a promising tool for early cancer detection and personalized medicine. In a recent case study published in OMICS: A Journal of Integrative Biology, researchers used LMOM to detect a precancerous pancreatic tumor in a patient who had undergone annual blood-based monitoring. The tumor was successfully removed through surgical intervention, highlighting the potential of LMOM for improving patient outcomes.
